Carregant...

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial

OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared patient‐reported outcomes (PROs) in patients with RA treated with tofacitinib or placebo in combination with conventional disease‐modifying antirheumatic drugs (DMARDs). METHODS: In a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arthritis Care Res (Hoboken)
Autors principals: Strand, Vibeke, Kremer, Joel M., Gruben, David, Krishnaswami, Sriram, Zwillich, Samuel H., Wallenstein, Gene V.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5413813/
https://ncbi.nlm.nih.gov/pubmed/27565000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.23004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!